Retatrutide Triple-Agonist Research
Retatrutide hits three receptors at once and is posting weight loss numbers no GLP-1 has touched. Here's what the trial data and 2026 research show.
Retatrutide is a synthetic single-molecule triple agonist peptide that binds the GLP-1, GIP, and glucagon receptors simultaneously, the newest entrant in the incretin research class after semaglutide and tirzepatide. It is still in clinical trials, but if 2024 was the year of tirzepatide and 2025 belonged to compounded GLP-1s, 2026 is shaping up to be retatrutide's year: the early data has the obesity research community paying serious attention.
What Retatrutide Actually Is
One peptide binding three different incretin receptors is what sets retatrutide apart:
- GLP-1 receptor, same target as semaglutide
- GIP receptor, added in tirzepatide
- Glucagon receptor, new with retatrutide
That third receptor matters. Glucagon agonism increases energy expenditure (your body burns more at rest), which is mechanistically different from the appetite suppression that drives GLP-1 weight loss. Retatrutide is the first widely studied peptide to combine both.
The Trial Data That Got Everyone's Attention
Phase 2 (Eli Lilly, 2023-2024)
- •24.2% mean body weight reduction at 12 mg weekly over 48 weeks
- •17.5% at 8 mg, 8.7% at 4 mg
- •Continued weight loss with no plateau through week 48(1)
For context: tirzepatide at 15 mg in SURMOUNT-1 produced ~20.9% reduction at 72 weeks. Retatrutide hit a higher number, faster.
Phase 3 (TRIUMPH program, ongoing 2025-2026)
- •Multiple trials including obesity, type-2 diabetes, MASH, knee osteoarthritis
- •Read-outs expected through 2026 and 2027
Side Effect Profile
Retatrutide carries the standard incretin side effect profile, plus glucagon-related effects:
- •Nausea, vomiting, diarrhea (GLP-1 typical)
- •Increased heart rate (modest, dose-dependent)
- •Mild increases in fasting glucose at higher doses (glucagon effect, usually offset by GLP-1/GIP)
- •The same titration discipline that applies to semaglutide and tirzepatide applies here
Titration in the Trial Literature
The Phase 2 trial protocol used a gradual weekly dose-escalation design over several months to reach the study's target doses, consistent with the tolerability pattern seen across the incretin class. This article does not provide dosing, administration, or titration guidance; consult the primary trial publications and institutional research protocols directly for any research application.
Storage & Handling
Retatrutide is a sensitive peptide. Lyophilized vials must stay refrigerated. Once reconstituted with bacteriostatic water, use within 28 days. See peptide storage and reconstitution for the full protocol.
How It Stacks Up vs. Tirzepatide and Semaglutide
- •Semaglutide: GLP-1 only, ~14.9% peak weight reduction
- •Tirzepatide: GLP-1 + GIP, ~20.9% peak
- •Retatrutide: GLP-1 + GIP + glucagon, ~24.2% peak
For the deeper GLP-1 vs GIP comparison, see our semaglutide vs tirzepatide breakdown.
Buying Research Retatrutide in the USA
Retatrutide is widely available as a research peptide. Quality matters more here than for shorter peptides because the molecule is large and easy to truncate during synthesis. Demand:
- •HPLC purity ≥99%
- •Mass spectrometry confirming the full sequence
- •Lyophilized powder in tamper-evident vials
- •Cold-chain shipping
Browse research-grade retatrutide at our shop or estimate dosing in the calculator.
Frequently Asked Questions
Is retatrutide stronger than tirzepatide?
On weight reduction in Phase 2 data, yes, retatrutide outperformed every approved GLP-1 to date. But it's still in trials, so long-term safety data is more limited than for tirzepatide.
What does the glucagon receptor do?
Glucagon agonism increases resting energy expenditure (your body burns more calories at rest). It's a different mechanism from the appetite suppression of GLP-1.
When will retatrutide be FDA approved?
Phase 3 trials are running through 2025-2026, with potential approval in 2026 to 2027 if data supports it.
What does the research literature say about retatrutide administration?
The Phase 2 trial protocol used a gradual weekly dose-escalation design over several months to reach the study's target doses. This article does not provide dosing, administration, or titration guidance; consult the primary trial publications and institutional research protocols directly for any research application.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. PMID: 37366315.
*Disclaimer: All products referenced are intended strictly for in-vitro laboratory research and are not approved by the FDA for human consumption or therapeutic use.*
Disclaimer: This article is provided for scientific, research, and educational purposes only. It is not medical advice and is not intended to guide human or animal use of any substance. The compounds discussed are research materials, are not FDA-approved for human use, and are not for consumption. References are to published research and regulatory sources; consult a qualified professional for any health decision. See also our Editorial & Medical Disclaimer and Research Use Only Disclaimer.
Ready to Explore Peptides?
Browse our catalog or use the calculator for instant pricing.
